Accelerated Approval Program’s Future Is On The Line At Avastin Hearing
Executive Summary
Genentech and FDA’s Center for Drug Evaluation and Research seem to agree on one thing when it comes to deciding whether Avastin’s (bevacizumab) metastatic breast cancer indication should be withdrawn – the integrity and intent of the agency’s accelerated approval program are at stake.
You may also be interested in...
Accelerated Approval Remains “Viable Pathway,” FDA’s Woodcock Says
FDA’s accelerated approval program is alive and well now, and will remain a viable pathway in the future, despite concerns within the industry and investor communities that recent oncology regulatory actions are hastening the program’s demise.